Tags
Language
Tags
May 2024
Su Mo Tu We Th Fr Sa
28 29 30 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 1

Clinical Handbook of Psychotropic Drugs, 25th Edition

Posted By: readerXXI
Clinical Handbook of Psychotropic Drugs, 25th Edition

Clinical Handbook of Psychotropic Drugs, 25th Edition
by Ric M. Procyshyn, Kalyna Z. Bezchlibnyk-Butler
English | 2023 | ISBN: 0889376328 | 555 Pages | True PDF | 5.87 MB

The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists,physicians, pharmacists, nurses, and other mental health professionals.

• Independent, unbiased, up-to-date
• Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options
• Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug
• Potential interactions and side effects summarized in comparison charts
• With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
• Clearly written patient information sheets available for download as printable PDF files
This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.

New in this edition:

• Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion; Auvelity extended-release tablets)
• Antipsychotics updates include revised Clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia
• Mood Stabilisers sections on Lithium and Anticonvulsants extensively revised
• Dementia chapter includes a new section on Lecanemab (Leqembi), a fast-track FDA approved treatment for Alzheimer’s disease
• Treatment of Substance Use Disorders includes revisions to Buprenorphine dosing section to include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal
• Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetic chapters all substantially revised
• New formulations and trade names include: Invega Hafyera (paliperidone long-acting 6-monthly IM injection), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)